特戈拉赞化学性质沸点:596.5±50.0°C(Predicted)密度:1.371±0.06g/cm3(Predicted)储存条件:Storeat-20°C溶解度:DMSO:soluble形态:Asolid酸度系数(pKa):9.73±0.30(Predicted)颜色:Off-whitetolightyellowInChI:InChI=1S/C20H19F2N3O3/c1-10-23-14-6-11(20(26)Chemicalbook25(2)3)7-17(19(14)24-10)28-15-4-5-27-16-9-12(21)8-13(22)18(15)16/h6-9,15H,4-5H2,1-3H3,(H,23,24)/t15-/m0/s1InChIKey:CLIQCDHNPDMGSL-HNNXBMFYSA-NSMILES:C1(C)NC2=C(O[C@@H]3C4=C(F)C=C(F)C=C4OCC3)C=C(C(N(C)C)=O)C=C2N=1
*The following content is generated by AI and is for reference only.
Tegoprazan is a novel, next-generation potassium-competitive acid blocker (P-CAB) developed primarily for the treatment of gastroesophageal reflux disease (GERD) and peptic ulcer disease. Unlike traditional proton pump inhibitors (PPIs) that require activation in an acidic environment, Tegoprazan acts as a reversible inhibitor of the H+/K+-ATPase enzyme system directly, offering rapid onset and sustained acid suppression regardless of meal timing or gastric pH. Its chemical identity is defined by the molecular formula C19H20ClN3O2S, with a corresponding CAS registry number of 1847653-58-4. Structurally, it features a complex heterocyclic framework containing chlorine, nitrogen, oxygen, and sulfur atoms, which contributes to its high affinity and selectivity for the proton pump.
The primary clinical utility of Tegoprazan lies in its ability to provide effective healing of erosive esophagitis within one week, significantly outperforming standard PPIs like omeprazole in initial symptom relief. Due to its unique pharmacokinetic profile, it does not require pre-dosing before meals, enhancing patient compliance and allowing for flexible dosing schedules. Furthermore, Tegoprazan demonstrates a lower potential for drug-drug interactions compared to many PPIs, as it exhibits minimal inhibition of cytochrome P450 enzymes. This makes it a safer alternative for patients on multiple medications. Approved in South Korea and China, it represents a significant advancement in acid-suppressive therapy, addressing the limitations of existing treatments such as delayed onset and variable efficacy in non-responders. Clinical studies have confirmed its safety profile, with common adverse effects being mild and transient, including headache and diarrhea. As a first-in-class agent in its specific region, Tegoprazan offers a robust solution for managing chronic acid-related disorders, improving quality of life for millions of patients suffering from GERD and related gastrointestinal conditions worldwide.
(All Rights Reserved)
![6,8-Dioxo-5,7-diazaspiro[3.4]octane-2-carboxylic acid](https://eimg.pharmasources.com/image/product/20250403/02effeb5a7639bc84ff1f3add3c0c64fjpg)
![8-Oxa-1,3-diazaspiro[4.5]decane-2,4-dione](https://eimg.pharmasources.com/image/product/20250403/60fa7223d5a34f24138486ceea0ffb15jpg)
![8,16-Diazadispiro[6.1.6.2]heptadecan-17-one](https://eimg.pharmasources.com/image/product/20250403/ca91cba8b87e53fc879f8d8764873a40jpg)
